Brokers Issue New Targets On Exelixis, Inc. (NASDAQ:EXEL)

Ken Copeland
May 4, 2017

Oppenheimer Holdings also issued estimates for Exelixis' Q4 2017 earnings at $0.00 EPS, FY2017 earnings at $0.07 EPS, FY2018 earnings at $0.48 EPS, FY2019 earnings at $0.97 EPS, FY2020 earnings at $1.30 EPS and FY2021 earnings at $1.58 EPS.

Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the first quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones. The biotechnology company reported $0.05 EPS for the quarter, beating the Zacks' consensus estimate of ($0.01) by $0.06. The company earned $80.90 million during the quarter, compared to analysts' expectations of $65.23 million. During the same quarter in the prior year, the firm posted ($0.27) EPS.

Relative strength index (RSI-14) for Exelixis, Inc.

02/28/2017 - Exelixis, Inc. had its " rating reiterated by analysts at William Blair. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & worldwide trademark and copyright law.

On Tuesday, Shares of Exelixis, Inc. Exelixis now has an average rating of "Buy" and an average price target of $18.37. CIBC began coverage on shares of Exelixis in a research report on Thursday, March 16th.

Best time to invest in stock market is when things are on odd side, and it's not easy how to pick stocks. Finally, Zacks Investment Research downgraded shares of Exelixis from a "buy" rating to a "hold" rating in a research report on Wednesday, March 1st.

Budget 2018 likely to be advanced, expected in January next year
According to the minister, the state government would try to finish the current budget proceedings by December this year. A decision to this effect was taken during the state cabinet meeting held here today.

Over 29 million smartphones shipped to India in Q1: Counterpoint report
These are providing a way for current feature phone users to take advantage of low/no cost voice calls over the 4G LTE networks. Oppo is targeting various price segments like Rs 10,000-15,000 and Rs 20,000-Rs 25,000 to increase sales across the country.

Melania did not intend to troll her husband on Twitter
It featured a popular gif of Melania smiling at Trump, then frowning as soon as he turns around. Within an hour of the tweet being posted, Melania Trump's account liked it.

According to the the latest analyst ratings which have been released, 3 brokers have issued a rating of "buy", 3 brokers "outperform", 2 brokers "hold", 0 brokers "underperform" and 0 brokers "sell". Exelixis now has an average rating of "Buy" and an average price target of $18.37.

Exelixis, Inc. (NASDAQ:EXEL) yearly performance is 402.17% and net profit margin is -36.70%. Exelixis has a one year low of $4.25 and a one year high of $24.85. Exelixis, Inc. (EXEL) has the market capitalization of 6.72 Billion. The stock's 50 day moving average is $21.34 and its 200 day moving average is $18.25.

The company surged 1.09% and closed its last trading session at $22. Acrospire Investment Management LLC boosted its stake in Exelixis by 7.2% in the third quarter. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 6.88% with $276.32 Million sitting short, betting on future declines. Acrospire Investment Management LLC now owns 16,353 shares of the biotechnology company's stock worth $209,000 after buying an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company's stock. Also, insider Michael Morrissey sold 200,000 shares of the stock in a transaction dated Monday, March 6th.

On 3/13/2017 Charles Cohen, Director, sold 10,000 with an average share price of $21.82 per share and the total transaction amounting to $218,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

In other news, CFO Christopher J. Senner sold 11,000 shares of the firm's stock in a transaction that occurred on Friday, March 3rd. The disclosure for this sale can be found here.

Another critical number in evaluating a stock is P/E or the price to earnings ratio.

Other reports by Guamnewswatch

Discuss This Article